



# Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report from the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working parties

AROME\*,<sup>1</sup>

Accepted 24 March 2010

## Contents

1. Introduction.....	00
2. Materials and methods.....	00
2.1. AROME concept.....	00
2.2. Aims and scope of AROME guidelines.....	00
2.3. Manuscript writing.....	00
3. Results.....	00
3.1. Concept of minimal requirements vs. standard of care.....	00
3.2. Minimal requirements vs. standard of care in the main type of cancers around the Mediterranean Area.....	00
3.2.1. Prostate cancer.....	00
3.2.2. Bladder cancer.....	00
3.2.3. Lung cancer.....	00

**Abbreviations:** ACR, American College of Radiology; AJCC, American Joint Committee on Cancer; BCG, Bacillus Calmette–Guerrain; BED, biologically equivalent dose; BCS, breast conserving surgery; BRCA, breast cancer gene; CEA, carcinoembryonic antigen; ChemoT, chemotherapy; CISH, chromogenic in situ hybridisation; CDDP, cisplatin; CR, complete response/responder; CT, computed tomography; ENT, ear–nose–throat; ER, estrogen receptor; FIGO, International Federation of Gynecology and Obstetrics; FISH, fluorescence in situ hybridization; FOLFOX, 5 fluorouracil, leucovorin, oxaliplatin; Gy, Gray; HR, hormone-receptor; HT, hormone therapy; IHC, immunohistochemistry; IMRT, intensity modulated radiotherapy; LDH, lactate dehydrogenase; LH-RH, luteinizing hormone-releasing hormone; LV, lymphovascular; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; M-VAC, methotrexate, vinblastine, doxorubicin, and cisplatin; m, month; N+, nodes positive; PCI, prophylactic cranial irradiation; PE, etoposide; PR, progesterone receptor; PS, performance status; PSA, prostatic specific antigen; q, every; RT, radiotherapy; RDE, rectal digital examination; SBR, Scarff–Bloom–Richardson; SLNB, sentinel node biopsy; TNM, tumor-node-metastasis staging system; TURBT, transurethral resection of the bladder tumor; UICC, Union International Centre le Cancer; u/s, ultrasound; WHO, World health Organization; y, year; 3D-CRT, three-dimensional; 2D-EBRT, two-dimensional external beam RT.

\* Yazid Belkacemi, CHU Hôpital Henri Mondor et Université de Paris XII, 51 av du Maréchal de Lattre de Tassigny, Créteil 94000 Cedex, France. Tel.: +33 1 49 81 21 45 22; fax: +33 1 49 81 25 89.

E-mail address: [yazid.belkacemi@hmn.aphp.fr](mailto:yazid.belkacemi@hmn.aphp.fr).

URL: <http://www.aromecancer.org>.

<sup>1</sup> Working parties (WP) members: *Breast an cervix cancers WP*: Joseph Gligorov (Chair; France), Oliver Arsovski (Macedonia); Yazid Belkacemi (France), Mounir Bachouchi (Morocco); Frederique Penault-Llorca (France); Marie-Pierre Chauvet (France); Nuran Senel-Bese (Turkey); Maria Carla Valli (Italy). *Urology cancers WP*: Hamouda Boussen (Chair; Tunisia), Assem Al halabi (Syria), Assia Bensalem (Algeria), Michel Hery (Monaco), Agim Sallaku (Albania), Salvador Villa (Spain). *Gastro-intestinal WP*: Marc Ychou (Chair; France), David Azria (France), Kada Boualga (Algeria), Noureddine Bouaouina (Tunisia), Laurent Cals (France), Yoram Cohen (Israel), Fady Geara (Lebanon), Nikola Vasev (Macedonia), Haitam Nasrallah (Israel). *Head and Neck cancers WP*: Mahmut Ozsahin (Chair; Turkey-Switzerland), Abdel Benider (Morocco), Khaldoun Kerrou (France), Dhurata Korovesi (Albania), Abraham Kuten (Israel), Paolo Muto (Italy), Khaled Thabet (Palestinian Authority), Vladimir Todorovic (Montenegro). *Lung cancer WP*: Kamel Bouzid (Chair; Algeria), Yanes Bashar (Palestinian Authority-Switzerland), Alfredo Carrato (Spain), Mladen Filipovic (Montenegro), Cesare Gridelli (Italy), Nil Molinas Mandel (Turkey), Pelagia G. Tsoutsou (Greece), Abderrahim Zouhair (Morocco-Switzerland). *Collaborative Projects WP*: Yazid Belkacemi (Chair; France), Micha Bar Hana (Israel), Zvi Bernstein (Israel), Stella de Sabata (Italy), Mokhtar Hamdicherif (Algeria), Francois Lokiec (France), Monder Mahjoubi (Tunisia), Hugo Marsiglia (Spain), Younes Mahi (France - Algeria). *Coordination of the manuscript elaboration*: Joseph Gligorov (France), Pelagia G. Tsoutsou (Greece), Abraham Kuten (Israel), Hamouda Boussen (Tunisia), Fady Geara (Lebanon), Nuran Bese (Turkey), Yazid Belkacemi (France).

1040-8428/\$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.

doi:10.1016/j.critrevonc.2010.03.007

Please cite this article in press as: AROME . Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: Report from the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working parties. Crit Rev Oncol/Hematol (2010), doi:10.1016/j.critrevonc.2010.03.007

2		
		<i>AROME / Critical Reviews in Oncology/Hematology xxx (2010) xxx–xxx</i>
	3.2.4.	Breast cancer ..... 00
	3.2.5.	Carcinoma of the cervix ..... 00
	3.2.6.	Head and neck cancer ..... 00
	3.2.7.	Colorectal cancer ..... 00
4.	Discussion	..... 00
5.	Conclusions	..... 00
	Conflicts of interest	..... 00
	Reviewers	..... 00
	Acknowledgement	..... 00
	References	..... 00

## Abstract

Guidelines are produced in oncology to facilitate clinical decision making and improve clinical practice. However, existing guidelines are mainly developed for countries with a certain availability of means and cultural aspects are rarely taken into account. Around the Mediterranean Area, countries share common cultural backgrounds but also great disparities with respect to availability of means; current guidelines by most societies are not applicable to all of those countries. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) is a scientific organization for the promotion and overcoming of inequalities in oncology clinical practice around the Mediterranean Area. In an effort to accomplish this goal, members of the AROME society have developed clinical recommendations for most common cancer sites in countries around the Mediterranean Area. The structure of these recommendations lies in the concept of *minimal requirements vs. standard of care*; they are being presented and discussed in the main text.

© 2010 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** Guidelines; Recommendations; Cancer care; Mediterranean Area

## 1. Introduction

Diseases are rare in medicine charge as much fear of death and involving as many specialists as cancer care. However the main goal of cancer treatment is still curative. Because of the complexity of the strategy according to different factors as tumour stage, tumour biology, comorbidities but also economical and cultural aspects we need guidelines. A clinical practice guideline has been defined as: “systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances” Field and Lohr [1]. An enormous amount of publications appear every year to develop “guidelines” aiming to organize the abundant literature and to promote education and guidance to the oncologists in their decision making. The majority of these guidelines are performed by European and North American study groups addressing specific sites, stages and clinical situations without, however, considering specific availability of means.

This mainstay of treatment unfortunately cannot be achieved in the majority of countries globally, due to various reasons, such as socioeconomic conditions, limited education of involved professionals, inadaptability of a new modality due to the mentality or the cultural background of a given people, as well as lack of education for cancer prevention in a population. Finally, cancer incidence varies among different geographical areas in the world demanding a diverse adaptation of strategies against it and a distinct use of the available means. This is particularly true when countries around the Mediterranean Area (MA) are concerned [3–8].

More specifically, as far as the northern part of the MA is concerned, there are several socioeconomic discrepancies even among European countries; these are being clearly reflected to health issues and it is now known that adherence to guidelines is not uniform among European countries, not even among departments in the same country [9,10]. Furthermore, at the southern-eastern MA, cancer has not been recognized as a public health problem until the last 10 years in the countries of Northern Africa (Morocco, Tunisia, Algeria, Libya) and in the countries of Middle East (Egypt, Syria, Jordan, Lebanon); these countries had, until then, given priority to transmissible diseases [11]; a fact that has begun to change over the 80s, since the formation of national cancer registries in most of these countries [12–17].

## 2. Materials and methods

### 2.1. AROME concept

Association of Radiotherapy and Oncology of the Mediterranean Area (AROME; [www.aromecancer.org](http://www.aromecancer.org)) is a medical organization aiming the collaboration of oncologists and other health care professionals implied in cancer care working in the area. The scope of the Association is to recognize the special circumstances and issues in the MA, to discuss and acknowledge openly existing issues in order to improve the existing problems, with a special interest at overcoming disparities in cancer care by various actions. AROME’s special focus is placed on the promotion of education and training in cancer care in implied professionals and the communities around the MA.

## 2.2. Aims and scope of AROME guidelines

In that concept, in the first AROME meeting held in Naples in April 2007, oncologists around the MA met and presented epidemiologic data from their respective countries. This was the first step for the recognition of the specific epidemiologic characteristics in the area, followed by the next step of presenting and recognizing the availability of means to provide cancer care in the various countries. Ultimately it became evident that optimum means were not available in several countries, which led to the recognition of the fact that cancer care should be re-evaluated and guidelines for treating specific cancer sites should be revisited, since they are inapplicable for several countries in the area. As a second step of the concept, site-specific working groups consisting of oncologists from different disciplines and different countries of the MA were formed. During the second AROME meeting “AROME guidelines for cancer care around the Mediterranean Area” were generated according to a process of a formalized consensus.

These guidelines were structured in a basic way. It was decided that *Minimum requirements* should be proposed, consisting of the minimal actions any oncologist should be able to perform anywhere in order to provide the acceptable minimum cancer care. These guidelines aimed to form the basic level, and oncologists should recognize that it would be inappropriate to treat cancer patients without availability of these requirements. On the other hand they aimed to rationalize cancer care and make better management of the available means so as to treat more patients in a most cost-effective manner. Existing guidelines for optimum care in countries with limited resources proposed by organizations such as the International Atomic Energy Agency (IAEA), Breast Health Global Initiative (BHGI) [2,18–20] were also taken into account during the preparation of the recommendations for the MA.

Furthermore, the existing guidelines proposed by major societies for the countries with optimal resources around the MA were taken into account. Members of the panels tried however, to be more Mediterranean-needs oriented and to face routine situations in the Mediterranean countries as they were presented by AROME representatives. These guidelines aimed at stretching the need for political pressure by professionals to the respective governments; they aimed to become a useful tool for providing evidence that optimum care is achievable and to inspire pieces of action in this direction to increase the cancer care to a higher level. Moreover, they may serve as a baseline of optimum care in decision making by oncologists around the Mediterranean Area.

However, it cannot be emphasized enough that this meeting highlighted another important issue which these guidelines aim to underline: that the interdisciplinary approach and communication by the different specialists involved in cancer care is the most cost-effective strategy; it is free of charge, however it can lead to an organized decision making saving the patient a lot of useless discomfort

and intervening at optimum timings with optimum medical actions.

These guidelines were composed of recommendations based on the best evidence available at the time of the meeting, as they were reviewed by members of the panel. Each panel comprised of 8–9 cancer specialists of various specialties: radiation oncologists, medical oncologists, surgical oncologists, physicians of nuclear medicine and epidemiologists. These guidelines aim to be updated at a 3 years interval in order to include recent evidence-based study results, as well as the eventual progress in means in the limited resources countries, allowing for a shift from minimal to potentially standard of care guidelines. However, if a major evolution takes place for a given cancer site, “express” guidelines will be prepared at anytime by AROME panelists in order to include the latest change. It is crucial to confront these guidelines with the notion that they are dynamic documents, as already proposed by National Comprehensive Cancer Network (NCCN) for their respective guidelines [21]. AROME aims to include professionals from more disciplines involved in cancer care into the next guideline updates.

## 2.3. Manuscript writing

During the meeting in Istanbul, all the available scientific evidence concerning a specific disease site was presented by members of the panel and discussed upon. After the meeting, members of the panels communicated through e-mails and prepared the below presented tables and text, that were reviewed by the respective chairmen. The manuscript was prepared by several AROME representatives that had already participated in panels for different disease sites. The final manuscript was read and approved by all panel members and revisions were made after comments allowed to any member of the panel were received. Authors are currently active professionals in oncology in Mediterranean countries and might be considered experts in their field. No funding from the industry or participation of any of its representatives was allowed to ensure independence of guidelines development. No conflicts of interest exist for any member of the panel.

## 3. Results

### 3.1. Concept of minimal requirements vs. standard of care

As discussed in the manuscript “AROME epidemiology and means around the Mediterranean Area”, which is currently being prepared for publication, most common cancers in the MA are: lung, breast, prostate, bladder, cervical, head and neck and colorectal cancer. Thereby follows a set of tables presenting the guidelines for every important disease entity around the MA. These guidelines focus on these major issues:

Table 1  
Guidelines for prostate cancer.

Minimum requirements	Standard of care
<b>Screening</b>	<b>Screening</b>
Patient asymptomatic > 50 years PSA q 2 y + RDE by urologist	Patient asymptomatic > 50 years PSA annually + RDE by urologist
Symptomatic patient	Symptomatic patient
RDE	DRE
Total PSA	Total PSA
Endorectal ultrasound	Endorectal ultrasound <i>TRUS-guided biopsy</i>
<b>Indications of biopsy</b>	<b>Indications of biopsy</b>
Transrectal multiple biopsies done by urologist oriented by RDE	Biopsy under ultrasound ( <i>TRUS-guided biopsy</i> )
Minimal number of 8 cores	20 cores
Conventional histopathologic examination-Gleason score	<i>IHC</i> in addition to conventional histopathology
<b>Staging</b>	<b>Staging</b>
Clinical examination	All the minimum
TNM classification	<i>MRI</i>
Gleason score	<i>PET scan (optional)</i>
Pelvic CT-scan	
Bone scintigraphy	
<b>Treatment</b>	<b>Treatment</b>
Localized (D'Amico's criteria)	Localized (D'Amico's criteria)
Low risk	Low risk
<70 years	<70 years
Prostatectomy	Prostatectomy
RT	3D-CRT (IMRT and brachytherapy: optional)
>70 years	>70 years
2D-EBRT	3D-CRT (IMRT and brachytherapy: optional)
Prostatectomy (optional) watch and wait	Prostatectomy (optional) Watch and wait
Intermediate	Intermediate
<70 years	<70 years
Prostatectomy	Prostatectomy
2D-EBRT + short HT	3D-CRT (optional IMRT) + short HT
70 years	70 years
2D-EBRT + short HT	3D-CRT (optional IMRT) + short HT
High risk	High risk
<70 years	<70 years
2D-EBRT + prolonged HT	3D-CRT (IMRT and brachytherapy: optional) + prolonged HT
Adjuvant HT after surgery (pN+)	Adjuvant HT after surgery (pN+)
Adjuvant 2D-EBRT after surgery (margins (+)/pT3 or pT4)	3D-CRT (optional IMRT) after surgery (margins (+)/pT3 or pT4)
>70 years	>70 years
2D-EBRT – HT	3D-CRT (IMRT and brachytherapy: optional) + HT
Locally advanced disease non-metastatic	Locally advanced disease non-metastatic
2D-EBRT + HT	3D-CRT (optional IMRT) + HT
Patients with positive nodes	Patients with positive nodes
Patients operated	Patients operated
HT	HT
Patients non operated	Patients non operated
2D-EBRT-HT	3D-CRT (optional IMRT)-HT
<b>Treatment failures</b>	<b>Treatment failures</b>
Rising PSA after prostatectomy	Rising PSA after prostatectomy
>0.2 ng/ml	>0.2 ng/ml
PSA doubling time > 6 months bone scintigraphy and pelvis CT-scan	PSA doubling time > 6 months Bone scintigraphy and pelvis CT-scan
Clinical and/or radiological relapse	<i>MRI</i>
2D-EBRT-HT	Clinical and/or radiological relapse
Isolated PSA rising	3D-CRT (optional IMRT)-HT
HT	Isolated PSA rising
	3D-CRT (optional IMRT)-HT
<b>Metastatic disease</b>	<b>Metastatic disease</b>
HT	HT

Table 1 (Continued)

Minimum requirements	Standard of care
Palliative 2D-RT	Palliative RT <i>Metabolic therapy-chemoT</i>
Metastatic and locally advanced patients	Metastatic and locally advanced patients
Therapeutic window	Therapeutic window
Minimal initial treatment of 6–12 months of treatment until PSA decrease to <4 ng/ml	Minimal initial treatment of 6–12 months of treatment until PSA decrease to <4 ng/ml
Restart the treatment when PSA > 10 ng/ml	Restart the treatment when PSA > 10 ng/ml
Early retreatment reduce the rate of bone complications	Early retreatment reduce the rate of bone complications
Progression under HT	Progression under HT
2nd line HT (anti-androgen and LH-RH analogues)	2nd line HT (anti-androgen and LH-RH analogues)
Failure → chemoT	Failure → chemoT

- Prevention/screening when applicable.
- Diagnosis.
- Staging.
- Treatment.
- Follow-up.

Tables 1–7 outline briefly the proposed AROME *minimum requirements* vs. *standard of care*. Table 8 outlines the minimum *available means* necessary for the management of each disease site vs. the standard of care of available means. Herein follows a discussion of the main points that emerge from the tables, concerning each disease site.

### 3.2. Minimal requirements vs. standard of care in the main type of cancers around the Mediterranean Area

#### 3.2.1. Prostate cancer

For diagnosis of prostate cancer, fewer cores are demanded for the biopsy specimen, since the biopsy is not being undertaken under ultrasound. No immunohistochemistry is demanded for the evaluation of the biopsy specimen for a minimum care. No magnetic resonance imaging (MRI) is available everywhere to provide minimum acceptable care regarding staging. All this information will not adequately stage the patient as for treatment decisions. Conformal radiotherapy (RT), chemotherapy for hormonoresistant patients, ablatherapy, metabolic therapy or colioscopic surgery are necessary as minimum treatment but not available everywhere. It is questionable however, if the minimum requirement of hormone therapy can be available to every patient with prostate cancer. In our mind, the most important of these limitations is the unavailability of conformal RT, which does not allow for dose escalation, a treatment feature that has proved essential for optimization of prostate cancer care. Therefore, we believe that prompt clinical examination with rectal digital examination, PSA measurements, biopsies taken and conventional histopathology, will allow for treatment of prostate cancer with prostatectomy, RT or hormone therapy, provided availability of drugs and essential RT machines (simulator and linear accelerator) exist. This would be the minimal requirements for a center to be allowed to take care of prostate cancer anywhere in the world.

#### 3.2.2. Bladder cancer

Cystoscopy urine cytology and the possibility to perform a CT-scan at least of the pelvis and biopsies are adequate to stage the patient. Concerning treatment the ability to perform transurethral resection or intravesical instillations or even more selective cystectomy techniques combined with chemoradiotherapy would almost lead to optimal treatment. However, when no supportive units are available for concomitant radiochemotherapy and no BCG or chemotherapy instillations are available, the ability to perform cystectomy is of ominous importance and would serve as a basis of minimal requirement.

#### 3.2.3. Lung cancer

In lung cancer minimal requirements do not demand the use of fluorodesoxyglucose PET or mediastinoscopy for exclusion of unresectability. However, one must bear in mind that CT-scan alone is inadequate for staging and that absence of these means will lead to an increased number of unnecessary thoracotomies. However, the absence of conformal RT for dose escalation, or hospitalization units to allow for supportive care and make concomitant chemoradiotherapy possible is the two main limitations with the adoption of minimum guidelines, as well as the inability to exclude preoperatively the unresectable patients. The use of more hypofractionated regimens when RT is offered as sole modality, will lead to the sparing of resources when the scope of the intervention is, as in most cases mostly palliative.

#### 3.2.4. Breast cancer

In breast cancer, for early detection screening mammography cannot be proposed as a minimum requirement for MA. Public awareness and breast self examination are recommended. For the diagnosis and pathological reporting immunohistochemistry, reporting of lymphovascular invasion and sentinel node biopsy is not required. Mastectomy should be proposed as the surgical technique when RT is not available.

For follow-up, systematic pelvic ultrasound in women receiving tamoxifen, bone mineral density and left ventricular ejection fraction examinations are essential. We believe

Table 2

Bladder cancer.

Minimum requirements	Standard of care
For initial work-up in bladder cancer	For Initial work-up in bladder cancer
Clinical examination	Clinical examination
Cystoscopy	Cystoscopy
Biopsies	Biopsies ( <i>mapping biopsies including TUR biopsy of the prostate</i> )
Pelvic CT-scan	Pelvic and <i>chest</i> CT-scan
Urine cytology	Urine cytology
Bone scintigraphy	Bone scintigraphy
Treatment	Treatment
Carcinoma in situ (TIS/Ta/T1) (N0M0)	Carcinoma in situ (TIS/Ta/T1) (N0M0)
TURB	<i>Examination under anesthesia</i>
Single dose intravesical chemoT	TURB
(BCG or mitomycin)	Single dose intravesical chemoT
	(BCG or mitomycin)
Localized bladder cancer (T2 high grade, T3a)	Localized bladder cancer (T2 high grade, T3a)
Radical cystectomy	Radical cystectomy ± neoadjuvant cisplatin based chemoT ± adjuvant cisplatin based chemoT (if no neoadjuvant) or segmental cystectomy ± neoadjuvant cisplatin based chemotherapy ± adjuvant RT + cisplatin based chemotherapy (if no neoadjuvant) or <i>selective bladder sparing after maximal TURBT</i> (if no hydronephrosis) after neoadjuvant RT + chemoT or RT + CT
Possibly also: ±neoadjuvant cisplatin based chemoT ± adjuvant cisplatin based chemoT (if no neoadjuvant) RT + CT (concomitant if supportive care available)	
Bladder cancer node positive, M0	Bladder cancer node positive, M0
Preoperative N+	Preoperative N+
Primary chemoT	ChemoT + RT → evaluation with cystoscopy
Responders → secondary surgery	No tumor: follow-up or boost (RT) or surgery
Non responders → secondary surgery or RT + chemoT	Residual disease: cystectomy, or RT (if not prior), or palliative TURBT
Primary surgery → node positive	Primary surgery → node positive
Bladder cancer node positive after surgery	Bladder cancer node positive after surgery
Adjuvant chemoT without proved benefit	Adjuvant chemoT without proved benefit
No indication of adjuvant RT excluding epidermoid type	No indication of adjuvant RT excluding epidermoid type
Bladder cancer node positive	Bladder cancer node positive
RT + chemoT	RT + chemoT
Metastatic patients	Metastatic patients
Systemic palliative chemoT (M-VAC) or cisplatin-gemcitabin	Systemic palliative chemoT (M-VAC) or cisplatin-gemcitabin
Palliative chemoT	Palliative chemoT
Palliative RT	Palliative RT
Supportive care	Supportive care

that among the limitations of the minimal requirements, the most important is the absence of an organized mammographic screening for all women. Concerning treatment, it has provocatively been mentioned that when resources are really scarce, the only cost-effective strategy is surgery, which might be true in terms of economic definitions, however, around the MA we believe that there is availability of at least tamoxifen as adjuvant modality [22].

### 3.2.5. Carcinoma of the cervix

For cervical cancer, no colposcopy and no MRI and/or CT-scan are a prerequisite of diagnosis, while no lymphovascular invasion should be routinely reported in pathologic examinations. In treatment, no brachytherapy availability and no para-aortic lymph node dissection are minimal requirements, while no CT or MRI scans or clinical trials access is essential as a minimum requirement for follow-up. We believe that the vaccination issue as well as the gynecologic

examination under general anesthesia is important issues to be reflected upon that are missing from the minimum requirements. Although the vaccination cost is expected to be too much for vaccination to be offered in every limited resource country, one must bear in mind that cervical cancer is very common around the MA and the implementation of vaccination might actually prove cost-effective even by strict economic standards.

### 3.2.6. Head and neck cancer

No MRI, PET or PET/CT-scan, no panendoscopy and no assessment of Epstein-Barr virus (EBV) are a prerequisite of minimal guidelines for establishing a diagnosis. Moreover, no conformal RT, no taxane chemotherapy or endothelial growth factor receptor (EGFR) targeted therapy are an essential component of minimum treatment. We believe that the absence of conformal RT and targeted treatments is a limitation of the therapeutic potential of minimum guidelines. However,

Table 3

Lung cancer.

Minimum requirements	Standard of care
<b>Diagnosis</b>	<b>Diagnosis</b>
Exclude unresectability by	Exclude unresectability by
Clinical examination	Chest X-ray + CT (liver + adrenals included)
Chest X-ray	<i>FDG-PET</i>
Liver function tests and liver US	<i>Mediastinoscopy</i>
Bone scan only if clinical indications	<i>Biopsy through bronchoscopy or CT guidance</i>
CT (or MRI) of brain only if limited disease	
Above results + PS + serum sodium and LDH to assess the patient's likely prognosis	
<b>Treatment</b>	<b>Treatment</b>
<b>Stage I</b>	<b>Stage I</b>
Surgical resection	Surgical resection
Postoperative treatment	Postoperative treatment
IA (T1N0)	IA (T1N0)
Margins (–): observe or chemoT in high risk patients	Margins (–): observe or chemoT in high risk patients
Margins (+): RT	Margins (+): <i>resection</i> or RT
IB (T2N0)	IB (T2N0)
Margins (–): chemoT	Margins (–): chemoT
Margins (+): RT + chemoT	Margins (+): <i>resection</i> RT + chemoT concomitantly
Stage I: medically inoperable patients	Stage I: medically inoperable patients
Curative RT	Curative RT
Small tumours hypofractionated regimen	3D Conformal RT
	Stereotactic RT with BED of at least 100 Gy
<b>Stage II: favorable IIIA</b>	<b>Stage II: favorable IIIA</b>
Surgical resection	Surgical resection
Postoperative treatment	Postoperative treatment
IIA, favorable IIB (T1-2N1)	IIA, favorable IIB (T1-2N1)
Margins (–): chemoT, or chemoT + RT if adverse factors	Margins (–): chemoT, or chemoT + RT if adverse factors
Margins (+): chemoT or RT + chemoT	Margins (+): <i>resection</i> or chemoT or RT + chemoT
Favorable IIIA (T1-2N2)	Favorable IIIA (T1-2N2)
Margins (–): chemoT or RT + chemoT	Margins (–): chemoT or RT + chemoT
Margins (+): RT + chemoT concomitantly	Margins (+): <i>resection</i> or RT + chemoT concomitantly
<b>NSCLC stage IIIA-B (unfavorable)</b>	<b>NSCLC stage IIIA-B (unfavorable)</b>
T3-4, N1 superior sulcus tumor	T3-4, N1 superior sulcus tumor
Resectable: chemoT + RT (concomitant if possible) followed by surgery	Resectable: chemoT + RT (concomitant) followed by surgery
Marginally resectable: chemoT + RT (concomitant if possible) followed by evaluation and surgery or if unresectable definitive RT + chemoT	Marginally resectable: chemoT + RT (concomitant) followed by evaluation and surgery or if unresectable definitive RT + CT
Unresectable: chemoT + RT concomitantly if possible	Unresectable: chemoT + RT concomitantly
Chest wall T3N1: surgery or RT or chemoT or RT + chemoT concomitant if possible	Chest wall T3N1: surgery or RT or chemoT or RT + chemoT concomitant
IIIA: T3N2: unresectable	IIIA: T3N2: unresectable
chemoT + RT concomitantly if possible	chemoT + RT concomitantly if possible
IIIB: T4N1: surgery followed by chemoT	IIIB: T4N1: surgery followed by chemoT
T3N3: chemoT + RT concomitantly followed by consolidation chemoT	T3N3: chemoT + RT concomitantly followed by consolidation chemoT
	ChemoT + RT concomitantly followed by consolidation chemoT
<b>Stage IV (metastatic disease)</b>	<b>Stage IV (metastatic disease)</b>
ChemoT if PS: 0–2	ChemoT if PS: 0–2
2 drugs combination	2 drugs combination
CDDP with older drugs	Platinum or non-platinum-based
CDDP with 2nd or 3rd generation agents if available	<6 cycles, <4 if no response
<6 cycles, <4 if no response	As soon as possible (good PS)
As soon as possible (good PS)	Elderly: 1 drug
Elderly: 1 drug	2nd line CT if PS, DF interval good: docetaxel
Supportive care	3rd line: gefitinib
	Investigational agents, 2 cycles, if PD, cross over
<b>Follow-up</b>	<b>Follow-up</b>
History/physical examination	History/physical examination
Every 3 m first 2 y	Every 3 m first 2 y

Table 3 (Continued)

Minimum requirements	Standard of care
Every 6 m 2–5 y Every 1 y thereafter Chest radiographs: no Other diagnostic procedures: no, unless symptomatic patient	Every 6 m 2–5 y Every 1 y thereafter Chest radiographs: no Other diagnostic procedures: no, unless symptomatic patient
<i>SCLC staging</i> As in NSCLC	<i>SCLC staging</i> CT chest ± upper abdomen, hematological tests Bone scan, brain CT, bone marrow biopsy: when patient symptomatic
<i>SCLC treatment</i> Limited disease CDDP and etoposide (PE) Consolidation RT after Concurrent RT and CT PCI in CRs and good PRs	<i>SCLC treatment</i> Limited disease Concurrent chemoT+ RT with CDDP-etoposide 3D conformal RT IMRT RT gating PCI in CRs and good PRs
<i>Extensive disease</i> ChemoT: same regimens as for limited disease Second-line chemoT Response evaluation is recommended at least at the end of treatment by repetition of the initial radiographic tests Follow-up: no follow-up of asymptomatic patients	<i>Extensive disease</i> ChemoT palliative RT for palliation or in place of chemoT PCI for good responders

the most cost-effective strategy would certainly be the smoking cessation campaigns as well as limitation of alcohol use around the MA, which would limit considerably the incidence of head and neck cancer.

### 3.2.7. Colorectal cancer

For colorectal cancer, no organized national screening, no colonoscopy as part of the screening procedure and no oncogenetic counseling for people bearing familial risk are essential for minimum preventive care. No CT, no PET, no carcinoembryonic antigen (CEA) detection are essential parts of minimum diagnosis. This is also true for follow-up. For treatment, we believe that the absence of appropriate staging by CT or endorectal ultrasound before treatment decision and the unavailability of drugs such as oxaliplatin limit the chance of cure in the minimum guidelines.

## 4. Discussion

The Mediterranean has been the sea that has given birth to what is called today “the western civilization”. Various ancient or more recent people that have long interplayed with each other clearly share many common features concerning lifestyles, cultures and mentalities. On the other hand, there is a great disparity of socioeconomic structures among the countries surrounding the MA, which limits the possibility of cancer care uniformisation [23]. For instance, on the one hand, there are Mediterranean countries, such as Spain, Italy and Greece which are relatively wealthy and present cancer survival rates that are superior to those of northern European countries. This can be attributed to many reasons, most important of which seems to be the Mediterranean diet [23–27]. On the other hand, there are countries of North Africa and

the Eastern Mediterranean Region (EMR) that have among the lowest cancer survival rates in the world, although they sustain, as well, more or less the same mediterranean diet [28,29]. This is obviously due to the lack of education, the lack of organized cancer care and limited resources.

Data are striking. The relative 5-year survival rates for breast cancer range from 80% or higher in North America to 38.8% Algeria, while in Italy and France survival rates range from 70% to 79% [30]. For colon cancer, the relative 5-year survival is approximately 60% in North America and 40% or lower in Algeria, while in Spain and France it ranges from 54% to 57%. The rates of survival for prostate cancer are 92% in the United States and less than 40% in Algeria [30].

At this point, one should acknowledge the lack of publications in the field and even the lack of formal national (or only regional) cancer registries in several countries. Therefore, before discussing this work, it is important to highlight the relative lack of evidence and also the fact that personal experiences from professionals currently working in the area were taken into serious account. One could argue that this is not a totally evidence-based, but also an opinion-based report and this is not completely wrong, as the lack of publications for the description of the exact situation in many among the countries of interest made it imperative that some personal opinions of oncologists practicing in these countries gained special attention and were thoroughly discussed among the working parties.

The purposes of clinical practice guidelines are to improve the quality of patient care (namely survival and quality of life) and assist clinical decisions by rationalizing the use of available resources and prioritizing research goals [3,31]. Guidelines have proven to be efficient in patient outcomes, at least in industrialized countries and tools to standardize guidelines have been developed [32–39]. Heterogeneity in



Table 4

Breast cancer.

Minimum requirements	Standard of care
Primary prevention in BRCA mutated patients Ovarian ablation to consider regarding the parity	Primary prevention in BRCA mutated patients Ovarian ablation to consider regarding the parity
Secondary prevention/early detection Aware women and general practitioner about the risk of breast cancer and educate about clinical breast examination	Secondary prevention Organized <i>screening</i> mammography for every women after age of 50 every 2 years <i>Systematic mammography yearly for the patient with previous treated breast cancer</i> <i>Patient with high risk and followed in specialized centers</i>
Mammography quality criteria At least 2 orthogonal incidences ACR classification Systematic comparison in case of previous mammography ACR guidelines	Mammography quality criteria At least 2 orthogonal incidences ACR classification Systematic comparison in case of previous mammography ACR guidelines
Diagnosis Pathology confirming the diagnosis of cancer (positive cytology acceptable) Clinical breast examination Imaging (preferentially mammography, if not available U/S)	Diagnosis Pathology ( <i>surgery or guided biopsy</i> )  Clinical breast examination Mammography <i>and</i> U/S
Staging Pathologic reporting Malignancy and type Invasiveness SBR, grade pT pN Margins (+ or –) Conserve primary tumor 10 years minimum	Staging Pathologic reporting Malignancy and type Invasiveness SBR grade pT pN Margins (+ or –) Conserve primary tumor 10 years minimum <i>IHC for HER2 (FISH or CISH if needed), ER, PgR</i> <i>IHC for SLNB</i> <i>LV invasion</i>
Initial work-up after pathology results Gynecological examination According to clinical examination	Initial work-up after pathology results Gynecological examination According to clinical examination <i>According to pathological results</i> <i>Stage I: no systematic work-up</i> <i>Stage II-III: Bone, Thoracic and abdominal imaging</i> <i>Cardiac, liver and hematological function in case of chemotherapy</i>
Primary treatment decision T0–T3 mastectomy with axillary clearance or when at least 2D-EBRT available: BCS + RT T4d and/or N2 begin with systemic treatment T4 a, b, c begin with local treatment and do axillary clearance in case of surgery	Primary treatment decision T0–T3 mastectomy or BCS + RT  Axillary clearance or <i>SLNB if T0–T1 and N0</i> T4d begin with chemoT  T4 a, b, c and/or N2 begin with systemic treatment and do axillary clearance in case of surgery
Surgery quality control Macroscopic complete excision of the cancer In case of BCS cancer excision from the skin to pectoralis muscle Lumpectomy piece oriented for pathologist Optimal axillary dissection with aim to be informative (min 6 lymph nodes in the axillary specimen)	Surgery quality control <b>ALL THE MINIMAL</b> <i>Choice of surgical technique (lumpectomy or mastectomy)</i> <i>Clips to guide radiotherapists in case of boost</i> <i>SLN procedure</i>  <i>Specialized oncology surgeon for breast</i>
Adjuvant treatment strategies  2D-EBRT in case of BCS or pN+ after mastectomy Tamoxifen for 5 years for all patients in case of unknown or positive hormone receptor	Adjuvant treatment strategies <i>Multidisciplinary approach</i> 2D/3D-EBRT of BCS or pN+ after mastectomy Tamoxifen for 5 years for all patients in case of unknown or positive hormone receptor if not menopausal

Table 4 (Continued)

Minimum requirements	Standard of care
PolychemoT regimens containing cyclophosphamide and doxorubicin (in case of no cardiac dysfunction) are recommended for pN+ or pN0 and HR– (if you have the information). Minimum: 4 cycles Trastuzumab for 1 year in case of HER2+ patients (if HER2 status was tested)	Antihormonal treatment containing <i>aromatase inhibitors</i> independently of the strategy (upfront, sequential or extended). Menopausal status is initially defined before any chemotherapy PolychemoT regimens containing cyclophosphamide and doxorubicin (in case of no cardiac dysfunction) are recommended for pN0, HER2– and HR–. The number of cycles are 4–6 PolychemoT regimens containing <i>taxane</i> , cyclophosphamide and doxorubicin (in case of no cardiac dysfunction) are recommended for pN+ or pN0 and HER2+. The number of cycles are 6–8 Trastuzumab for 1 year in case of HER2+ patients
Follow-up concerning the cancer Clinical exam: every 6 months the first 2 years, then every year  Mammography: every year	Follow-up concerning the cancer Clinical exam: <i>every 3 months</i> the first year, then every 6 months for 2 years more, then every year Mammography: every year
Follow-up concerning the cancer treatment Clinical exam: every 6 months the first 2 years, then every year  Gynecologic examination (if tamoxifen treatment)	Follow-up concerning the cancer treatment Clinical exam: <i>every 3 months</i> the first year, then every 6 months for 2 years more, then every year <i>Transvaginal US</i> in case of gynecological symptoms <i>Bone mineral density</i> at the beginning <i>LVEF</i> to be considered for patients who will receive anthracyclines and/or trastuzumab and/or RT for left sided breast cancer

Table 5  
Cervical cancer.

Minimum requirements	Standard of care
Prevention Organized screening Sexual education	Prevention <i>Vaccination</i> and organized screening Sexual education
Organized screening Individual invitation to the women Control of quality of the test Quality insurance for follow-up and treatment of the positive test Data collection WHO	Organized screening Individual invitation to the women Control of quality of the test Quality insurance for follow-up and treatment of the positive test Data collection <i>and link with cancer registry</i> WHO
Diagnosis and preclinical staging Pathology (biopsy) Gynecologic examination  Abdomino pelvic US Chest X-ray FIGO classification	Diagnosis and preclinical staging Pathology (biopsy) Gynecologic examination <i>under anesthesia in presence of surgeon and radiotherapist</i> <i>Colposcopy</i> in case of occult disease <i>Abdominal CT-scan</i> Chest X-ray <i>Pelvic CT-scan or MRI</i> if available FIGO classification
Staging Pathologic reporting Malignancy and type Stromal invasion Grade pT pN Margins (+ or –)	Staging Pathologic reporting Malignancy and type Stromal invasion Grade pT pN Margins (+ or –) <i>LV invasion</i>
Primary treatment decision Multidisciplinary (surgeon, radiotherapist)  Operable (until IIa)	Primary treatment decision Multidisciplinary (surgeon, radiotherapist, <i>radiologist, medical oncologist</i> ) Operable (until IIa)

Table 5 (Continued)

Minimum requirements	Standard of care
Surgery first and additional therapy depending of pTpN	Surgery <i>eventually after brachytherapy</i> and additional therapy depending of pTpN
Inoperable (IIb-IV) Concomitant RT + chemoT (platinum-based) and additional therapy depending on response	Inoperable (IIb-IV) Concomitant RT + chemoT (platinum-based) and additional therapy depending on response
Surgery quality control Wertheim Pelvic lymphadenectomy	Surgery quality control Wertheim Pelvic lymphadenectomy <i>and if positive para-aortic lymph nodes dissection</i>
Quality control in complete excision	Quality control in complete excision
Second step treatment	Second step treatment
Operated Postoperative 2D-EBRT in case of deep cervical invasion and/or pN+ (with concomitant platinum-based chemoT) Postoperative brachytherapy if margins (+) and/or parametrial invasion	Operated Postoperative 2 or 3D-EBRT in case of deep cervical invasion and/or pN+ (with concomitant platinum-based chemoT) Postoperative brachytherapy if margins (+) and/or parametrial invasion
Not operated Not responders: no recommendations Responders: surgery and/or brachytherapy	Not operated Not responders: no recommendations Responders: surgery and/or brachytherapy
Follow-up concerning the cancer Clinical and gynecological exam: every 3 months for the first 2 years, then every 6 months for 2 years, then yearly Vaginal smear Abdominal and pelvic US every 6 months the first 3 years Chest X-ray if symptoms	Follow-up concerning the cancer Clinical and gynecological exam: every 3 months for the first 2 years, then every 6 months for 2 years, then yearly Vaginal smear Abdominal and pelvic US every 6 months the first 3 years If positive US, <i>abdominal CT-scan and pelvic CT-scan or MRI every year</i> Chest X-ray if symptoms
Follow-up concerning the cancer treatment Clinical and gynecological exam: every 3 months for the first 2 years, then every 6 months for 2 years, then yearly Renal function (glomerular filtration) in case of cisplatinum-based chemotherapy	Follow-up concerning the cancer treatment Clinical and gynecological exam: every 3 for months the first 2 years, then every 6 months for 2 years, then yearly Renal function (glomerular filtration) in case of cisplatinum-based chemotherapy

Table 6  
Head and neck cancer.

Minimum requirements	Standard of care
Diagnosis Patient should be examined by a head and neck surgeon Imaging for loco regional and systemic work-up: CT  Biopsy “primary or nodal”  TNM staging according to latest AJCC/UICC staging systems Dental assessment Nutritional and general health assessment by a medical doctor	Diagnosis Patient should be examined by a <i>multidisciplinary team</i> Imaging for locoregional and systemic work-up: <i>CT, MRI and PET or PET/CT</i>  <i>Panendoscopy and biopsy “primary or nodal” including IHC and immuno-phenotyping</i> TNM staging according to latest AJCC/UICC staging systems Dental assessment Nutritional by and <i>nutritional specialist</i> and general health assessment by a medical doctor. <i>In nasopharyngeal cancer EBV</i> assessement before treatment and during follow-up.
Metastatic disease Palliative treatment with medical and nutritional support	Metastatic disease Palliative treatment with medical and nutritional support
Follow-up Clinical ENT examination Every 2/3 months for the first 2 years Every 6 months until 5 years Yearly thereafter	Follow-up Clinical ENT examination Every 2/3 months for the first 2 years Every 6 months until 5 years Yearly thereafter

Table 7  
Colorectal cancer.

Minimum requirements	Standard of care
Colon cancer	Colon cancer
Diagnosis	Diagnosis
Prevention	Prevention
Media campaigns educating on healthy diet, physical activity and healthy way of life in general	<i>Nationally organized screening program</i>
	<i>Implications of different factors of public health and their associations</i>
Treatment	Treatment
Stage: non-metastatic disease	Stage: non-metastatic disease
Surgery without any delay	Surgery <i>within 15 days</i> after work-up
At least 8 analysed nodes on pathologic report	Choice between <i>laparoscopy or laparotomy</i> according to the surgeon's practice
Minimal margin: 5 cm	
Stage: non-synchronous metastatic disease	Stage: non-synchronous metastatic disease
Resectable	Resectable
Easily class 1 surgery with or without peri operative chemoT	Easily class 1 surgery with or without peri operative FOLFOX
Non-easily class 2: preoperative chemoT	Non-easily class 2: preoperative chemoT
	PET scan in the work-up
	Perioperative US
	Radiofrequency accessibility
Non-resectable metastatic disease	Non-resectable
5FU-based chemotherapy	Access at <i>all the effective drugs including targeted therapies</i>
In all cases multidisciplinary decision is necessary	
Follow-up	Follow-up
Clinical examination every 3–6 months	Clinical examination every 3–6 months
Abdominal US every 3–6 months	Abdominal US every 3–6 months
Chest X-ray every year	Chest X-ray every year
Coloscopy at 3 years (1 year if preoperative incomplete coloscopy)	Coloscopy at 3 years (1 year if preoperative incomplete coloscopy)
	<i>CEA monitoring</i>
	<i>CT body scan</i>
	<i>PET scan if elevated CEA <math>\geq 25\%</math></i>
Rectal cancer	Rectal cancer
Staging-operability	Staging-operability
Digital examination	Digital examination
Coloscopy	Coloscopy
Body CT-scan	Body CT-scan
	<i>Endorectal US</i>
	<i>Pelvic MRI</i>
Treatment	Treatment
T1–T2 surgery alone	T1–T2 surgery alone
T3–T4 preoperative RT (no Cobalt)	T3–T4 preoperative RT (no cobalt)
Short delay	Short delay
Surgery 3–8 weeks after RT	Surgery 3–8 weeks after RT
	<i>ChemoT <math>\pm</math> RT</i>
	<i>Decision based on EER and/or MRI</i>

guideline development is controversially seen: while some think it is a draw back to the uniformity of cancer patient care, our group believes that such heterogeneity is necessary if countries with limited resources or diverse cultures are to be taken into account. Other investigators agree and promote guideline flexibility as a necessary characteristic for meeting distinct needs [40–42].

Existing international guidelines address circumstances in countries where a certain wealth exists; moreover, they address the needs of people living mainly in northern Europe or northern America, that have a distinct socio-cultural issue from those of the MA. Adherence to these guidelines can be

measured, as shown by ASCO/NCCN measures, for instance [43].

Guidelines intend to have implications in making treatment decisions with an impact on the patient–physician relationship. However, the intrinsic cultural and religious beliefs and the level of education of the patients can vary significantly in the MA. Therefore, existing “western” guidelines cannot be directly adopted by most countries of the MA. Some recent publications have addressed the issue of developing guidelines for countries with limited resources [2,19–21,44–49]. These can be valuable tools for physicians working in such countries, since they acknowledge

Table 8  
Minimum requirements of *available means* vs. standard of care.

Minimum requirements	Standard of care
Prostate cancer	Prostate cancer
Availability of treatment modalities	Availability of treatment modalities
LH-RH analogues	LH-RH analogues
Anti-androgens	Anti-androgens
Biphosphonates	Biphosphonates
Prostatectomy plus node dissection	Prostatectomy plus node dissection
Conventional radiotherapy (RT) (Cobalt)	Conformal RT
Conventional simulator	ChemoT for hormone-resistant patients
	Ablathermy
	Coelioscopic surgery
	Metabolic therapy
Bladder cancer	Bladder cancer
TURBT	TURBT
BCG therapy for 1 year	BCG therapy for 1 year
Cystectomy ± prostatectomy	Cystectomy ± prostatectomy
Lymph node dissection	Lymph node dissection
No defined number of nodes	No defined number of nodes
RT	RT + chemoT concomitantly
ChemoT (cisplatin-based)	
Lung cancer	Lung cancer
Diagnosis: radiograph, u/s, CT, bronchoscopy, histopathology laboratory	Diagnosis: radiograph, u/s, CT, bronchoscopy, histopathology laboratory, plus MRI, PET-CT (optimum care), mediastinoscopy
Treatment	Treatment
ChemoT: outpatient unit, cisplatin, etoposide availability	ChemoT: outpatient unit, cisplatin, etoposide availability plus: 2nd line or 3rd line agents
RT: conventional 2D simulator, cobalt unit	RT: 3D simulator, linear accelerator plus: IMRT, RT gating
Breast cancer	Breast cancer
Quality of breast cancer care organizations	Quality of breast cancer care organizations
Oncology team have to participate to quality control programs	Oncology team (epidemiologist, surgeon, radiotherapist, pathologist, radiologist, medical oncologist, nurses, supportive care, psychologists) have to participate to quality control programs
Give to patients information concerning diagnosis and treatment according to the standards of care of the unit	Give to patients information concerning diagnosis and treatment according to the standards of care of the unit
Access to supportive care and optimal analgesia in case of pain.	Access to <i>clinical trials</i>
Cervical cancer	Cervical cancer
Quality of cervix cancer care organizations	Quality of cervix cancer care organizations
Oncology team have to participate to quality control programs	Oncology team (epidemiologist, gynecologist, surgeon, radiotherapist, pathologist, radiologist, medical oncologist, nurses, supportive care, psychologists) have to participate to quality control programs
Give to patients information concerning diagnosis and treatment according to the standards of care of the unit	Give to patients information concerning diagnosis and treatment according to the standards of care of the unit
Access to supportive care and optimal analgesia in case of pain	Access to clinical trials

their needs more openly and offer practical suggestions for the optimum way to treat a patient regarding availability of means.

To our knowledge, the only published guidelines for limited resource countries concern breast and lung cancer [2,19–21,44–49]. These guidelines were read carefully by members of our panels and were adapted to the needs of the Mediterranean countries, according to the panelists' opinion. Interestingly, members of our panel have participated in these previously mentioned panels for the development of guidelines in limited resources countries. These guidelines are a first important step in the way of acknowledging the importance of adapting guidelines' to the availability of resources [50–52].

Inequalities in the MA include the different socio-economic status between countries such as Spain or Italy to countries such as Egypt, the Palestinian authority or Algeria. Among rich countries, there is little correlation between gross national product (GNP) per person and life expectancy. Greece for example, with a GNP of US\$17,000, has a life expectancy of 78.1 years; the USA, with a GNP \$34,000, has a life expectancy of 76.9 years. Very often, populations with similar but restricted incomes present strikingly different health records; therefore the social gradient in health is a particular challenge [53,54].

Efforts by major organizations have already been made for ameliorating the situation in limited resources countries. WHO's cancer control programmes in the EMR have focused

on developing programs and support to countries for setting up their own cancer registries, in a region where the main reasons for the recent increase in cancer-related mortality are increasing tobacco use; higher life expectancy and changes in lifestyle—particularly diet [55]. Only 50% of EMR countries have cancer control plans and major gaps in national capacity to prevent, detect, and manage cancer in the EMR exist, while national guidelines for the clinical management of common cancers are available in one third of these countries [55].

Another issue is the lack of access to cost-effective anti-cancer drugs, which are available in most northern countries, yet not affordable in more than 50% of the EMR, as well as the lack of good quality cancer data that poses obstacles to the formation of an evidence-based policy formation; most of the cancer data being derived from hospital-based registries (55). Combating the tobacco epidemics is a priority to WHO, with health education in school being pivotal for this issue, while other challenges include the establishment of cancer surveillance systems, primary prevention programmes, and the availability of optimal standards for the management and palliation of common cancers [55,56].

The purpose of the AROME guidelines is to bring to light the vast spectrum of possible practices adopted in the MA, to trigger conversation, to serve as a useful tool for any professional dealing with cancer in the area and to promote a multidisciplinary, cost-effective up-to-date management of cancer in the region. As already discussed, AROME guidelines do not aim to “teach” or “instruct” professionals in the MA. They aim to form a basis for the development of practices and policies leading from the *minimum requirements* to grow to the *standard of care*. However, their penetrance through the Mediterranean populations remains to be seen.

These *minimum requirements* provide a baseline for the best implementation of scarce resources to cancer care. On the other hand, they should not be seen by any means as competent. These guidelines aim to be updated due to the eventual amelioration of available means and the purpose of AROME is that someday they will coincide with *standard of care* in all countries around the MA.

However, this demands a great deal of political will, cooperation and organization of resources. The purpose of AROME is to become a tool for public pressure for the homogenization of resources around the MA, through educational interventions to health professionals and to the public and eventually the taking of political stands for optimization of the available means and the implementation of new techniques and technologies in countries around the MA.

The development of health systems and relief of poverty means taking action on the social determinants of health [54]. Health status should be of concern to all policy makers, not merely those within the health sector, because as underlined by Marmot M: “if health of a population suffers it is an indicator that the set of social arrangements needs to change” [55]. This is especially important because, in many countries, inequalities in health have been increasing [56–59]. The development of evidence-based policies, mobilization

and appropriate allocation of resources, government commitment to legislation, education and international collaboration will eventually bring a more uniform health situation across the MA [24].

Initiatives in this direction have already been taken by the World Health Organization’s STEPwise programme [60], by the International Atomic Energy Agency’s PACT programme [61], the Global Summit Treatment and Allocation of Resources Panel and Breast Health Global Initiative [2], the WHO Framework Convention for Tobacco Control (WHO FCTC) [62]. Moreover, the Commission on Social Determinants of Health examines inequalities in health between countries and inequalities within [54]. At this point, it should be underlined that AROME is currently working in close collaboration with international organisations of cancer care and is aiming to strengthen these collaborations, a way to overcome the disparities and avoid duplication of efforts.

## 5. Conclusions

Governments must take public concerns about cancer seriously [63]. Collecting sound data and aligning cancer registries with international standards is an urgent public health demand. Screening through national initiatives, peoples’ education and prevention, early diagnosis and decent cancer treatment are a realistic goal. As underlined by the Commission on Social Determinants of Health, it is challenging to convince policy makers that the health of the population is important because it is a measure of whether a population is benefiting as a result of a set of social arrangements [54]. Therefore, such improvement will indicate that society has moved in a direction of meeting human needs [64]. AROME “minimal requirements and standard of care” aimed to meet the distinct needs of the health systems of the countries around the MA, as well as the specific demands of patients and health professionals within them. In some countries such document that point out on “minimal requirement to treat patients” could be a mean of pressure on the local politics to review the allowed means for cancer care. In addition the impact of AROME guidelines on health outcomes will be the ultimate criterion by which our guideline should be confronted and further ameliorated in future updates.

## Conflicts of interest

The authors state no actual conflicts of interest.

## Reviewers

Michael J. Koukourakis, M.D., University Hospital of Thrace, Radiation Therapy Unit, Alexandroupolis, Greece.

Jean-Bernard Dubois, M.D., Val d'Aurelle Cancer Institute, Department of Radiation Oncology, Montpellier, France.

## Acknowledgement

The authors would like to acknowledge Frances Godson for the English review.

## References

- [1] Committee to Advise the Public Health Service on Clinical Practice Guidelines Institute of Medicine. In: Field MJ, Lohr KN, editors. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press; 1990.
- [2] Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the breast health global initiative. *World J Surg* 2008;32:2578–85.
- [3] Pentheroudakis G, Stahel R, Hansen H, Pavlidis N. Heterogeneity in cancer guidelines: should we eradicate or tolerate? *Ann Oncol* 2008;19:2067–78.
- [4] Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harm of clinical guidelines. *BMJ* 1999;318:527–30.
- [5] Fervers B, Philip T, Browman GP. Critical appraisal of the MCR of the European Society for Medical Oncology: challenges for a European framework for the development of clinical practice guidelines. *Ann Oncol* 2002;13:1507–10.
- [6] Ward E, Halpern M, Schrag N, Schrag NM, Bian J, Chen AY. Association of insurance with cancer care utilisation and outcomes. *CA Cancer J Clin* 2008;58:9–31.
- [7] Norheim OF. High-cost therapy. Ethical principles of allocation of scarce resources. *Tidsskr Nor Laegeforen* 1992;112:3115–8.
- [8] World Health Organisation. Science and technology for health promotion in developing countries. *WHO Chron* 1979;33:399–406.
- [9] Brenner H, Hoffmeister M, Haug U. Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. *Br J Cancer* 2008;99:532–5.
- [10] Cheung WY, Pond GR, Rother M, et al. Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer. *Clin Colorectal Cancer* 2008;7:191–6.
- [11] Fissah A. Evidence based medicine. The facts in the South countries. *Rev Mal Respir* 2006;23:10S13–10S.
- [12] Report on the third intercountry meeting on cancer control and prevention. Cairo, Egypt; 2001. WHO-EM/NCD/029/E/1/02/02/07.
- [13] Adib SM. Lebanon National Cancer Registry. <http://www.emro.who.int/ncd/publications/NCR-LEB-02>.
- [14] Al-Kayed S. Jordan National Cancer Registry. <http://www.mecc.cancer.gov/publications/epidem.html>.
- [15] Hamouda D, Bouhadef A. Registres des tumeurs d'Alger. Publications annue, vol. 4. chemin El Bakr, Alger: Institut national de sante Publique; 2003.
- [16] Parkin DM, Ferlay J, Hamdi Cherif M. Cancer in Africa: epidemiology and prevention. IARC Scientific publications no. 153. IARC Press Lyon; 2003. p. 414.
- [17] Chaouki N, El Gueddari B. Epidemiological descriptive approach of cancer in Morocco through the activity of the national institute of oncology 1986–1987. *Bull Cancer* 1991;78:603–9.
- [18] Macbeth FR, Abratt RP, Cho KH, Stephens RJ, Jeremic B, International Atomic Energy Agency. Lung cancer management in limited resource settings: guidelines for appropriate good care. *Radiother Oncol* 2007;82:123–31.
- [19] Anderson BO, Shyyan R, Eniu A, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. *Breast J* 2006;12:S3–15.
- [20] Eniu A, Carlson RW, Aziz Z, et al. Global summit treatment and allocation of resources panel. Breast cancer in limited-resource countries: treatment and allocation of resources. *Breast J* 2006;12:S38–53.
- [21] [http://www.nccn.org/professionals/physician\\_gls/recently\\_updated.asp](http://www.nccn.org/professionals/physician_gls/recently_updated.asp).
- [22] Love R. Clinical research in the developing world. In: ASCO breast cancer symposium 2008 educational book. 2008. p. 68–9.
- [23] Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. *Oncogene* 2006;25:3756–70.
- [24] La Vecchia C, Bosetti C. Diet and cancer risk in Mediterranean countries: open issues. *Public Health Nutr* 2006;9:1077–82.
- [25] Menendez JA, Lupu R. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). *Curr Pharm Biotechnol* 2006;7:495–502.
- [26] Rubba P, Mancini FP, Gentile M, Mancini M. The Mediterranean diet in Italy: an update. *World Rev Nutr Diet* 2007;97:85–113.
- [27] Bogani P, Visioli F. Antioxidants in the Mediterranean diets: an update. *World Rev Nutr Diet* 2007;97:162–79.
- [28] Omar S, Alieldin NH, Khatib OM. Cancer magnitude, challenges and control in the Eastern Mediterranean region. *East Mediterr Health J* 2007;13:1486–96.
- [29] Zeghichi-Hamri S, Kallithraka S. Mediterranean diet in the Maghreb: an update. *World Rev Nutr Diet* 2007;97:139–61.
- [30] Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol* 2008;9:730–56.
- [31] McCarthy M, Datta P, Khachatryan A, Coleman MP, Rachet B. Would compliance with cancer care standards improve survival for breast, colorectal and lung cancers? *J Epidemiol Community Health* 2008;62:650–4.
- [32] Smith TJ, Hilnner BE. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. *J Clin Oncol* 2001;19:2886–97.
- [33] Ray-Coquard I, Philip T, de Laroche G, et al. A controlled “before-after” study: impact of a clinical guidelines programme and regional cancer network organisation on medical practice. *Br J Cancer* 2002;86:313–21.
- [34] Shiffman RN, Shekelle P, Overhage M, Slutsky J, Grimshaw J, Deshpande AM. Standardising reporting of clinical practice guidelines: a proposal from the conference on guideline standardisation. *Ann Intern Med* 2003;139:493–8.
- [35] AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care* 2003;12:18–23.
- [36] ADAPTE. Manual for guideline adaptation. ADAPTE Group; 2007. <http://www.adapte.org>.
- [37] GRADE Working Group. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328:1490–7.
- [38] SIGN 50. A guideline developer's handbook. Edinburgh: Scottish Intercollegiate Guidelines Network; 2004. <http://www.sign.ac.uk/guidelines/fulltext/50/index.html>.
- [39] National Institute for Health Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2007. <http://www.nice.org.uk>.
- [40] Pavlidis N. Towards a convenient way to practice medical oncology. *Ann Oncol* 2007;18(S2). p. ii3–ii4.
- [41] Fervers B, Philip T, Haugh M, Cluzeau F, Browman G. Clinical practice guidelines in Europe: time for European co-operation for cancer guidelines. *Lancet Oncol* 2003;4:139–40.
- [42] Eisinger F, Geller G, Burke W, Holtzman NA. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. *Lancet* 1999;353:191–200.

- [43] Desch CE, McNiff KK, Schneider EC, et al. American society of clinical oncology/national comprehensive cancer network quality measures. *J Clin Oncol* 2008;26:3631–7.
- [44] Yip CH, Anderson BO. The breast health global initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries. *Expert Rev Anticancer Ther* 2007;7:1095–104.
- [45] Anderson BO, Carlson RW. Guidelines for improving breast health care in limited resource countries: the Breast Health Global Initiative. *J Natl Compr Cancer Netw* 2007;5:349–56.
- [46] Bese NS, Kiel K, El-Gueddari Bel-K, et al. Radiotherapy for breast cancer in countries with limited resources: program implementation and evidence-based recommendations. *Breast J* 2006;12:S96–102.
- [47] Anderson BO, Yip CH, Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. *Breast J* 2006;12:S54–69.
- [48] Shyyan R, Masood S, Badwe RA, et al. Breast cancer in limited-resource countries: diagnosis and pathology. *Breast J* 2006;12:S27–37.
- [49] Anderson BO. Breast healthcare and cancer control in limited-resource countries: a framework for change. *Nat Clin Pract Oncol* 2006;3:4–5.
- [50] V. Gupta, Clinical care in the developing world, p. 61–62.
- [51] E. Cazap, Breast cancer in Latin America, p. 63–65.
- [52] B.O. Anderson, The breast health global initiative: guideline implementation in low- and middle-income countries, p. 66–67.
- [53] United Nations. Human development report 2004. New York: United Nations Development Programme; 2004.
- [54] Marmot M. Social determinants of health inequalities. *Lancet* 2005;365:1099–104.
- [55] Khabir A. WHO's activities in the Eastern Mediterranean Region. *Lancet Oncol* 2003;4:6.
- [56] da Costa e Silva VL. Health consequences of the tobacco epidemic in West African French-speaking countries and current tobacco control. *Promot Educ* 2005;(4). p. 7–12, 54.
- [57] Donkin A, Goldblatt P, Lynch K. Inequalities in life expectancy by social class 1972–1999. *Health Stat Q* 2002;15:5–15.
- [58] Mackenbach JP, Bos V, Andersen O, et al. Widening socioeconomic inequalities in mortality in six Western European countries. *Int J Epidemiol* 2003;32:830–7.
- [59] Crimmins EM, Saito Y. Trends in healthy life expectancy in the United States, 1970–1990: gender, racial, and educational differences. *Soc Sci Med* 2001;52:1629–41.
- [60] <http://www.who.int/chp/steps/en/>.
- [61] <http://cancer.iaea.org/>.
- [62] <http://www.searo.who.int/en/Section1174/Section2469/Section2470.htm>.
- [63] Rawaf S, Dubois E, Khatib OM, Omar S. Cancer prevention and control in Eastern Mediterranean region. *BMJ* 2006;333(October):860–1.
- [64] Doyal L, Gough I. A theory of human need. London: Macmillan; 1991.